nach oben

Erschienen in:

02.03.2024 | Case Study

Effect of sarcopenia and frailty on outcomes among patients with brain metastases

verfasst von: Mervyn Jun Rui Lim, Zheting Zhang, Yilong Zheng, Ivan Wei Loon Khoo, Rhianne Caitlin Vaz Xin Ying, Sophie Jia Qian Koh, Ethanyn Lim, Pei Ing Ngam, Betsy Soon, Ying Liang Low, Li Feng Tan, Kejia Teo, Vincent Diong Weng Nga, Tseng Tsai Yeo

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Sarcopenia and frailty have been associated with increased mortality and duration of hospitalization in cancer. However, data investigating these effects in patients with brain metastases remain limited. This study aimed to investigate the effects of sarcopenia and frailty on clinical outcomes in patients with surgically treated brain metastases.

Methods

Patients who underwent surgical resection of brain metastases from 2011 to 2019 were included. Psoas cross-sectional area and temporalis thickness were measured by two independent radiologists (Cronbach’s alpha > 0.98). Frailty was assessed using the Clinical Frailty Scale (CFS) pre-operatively and post-operatively. Overall mortality, recurrence, and duration of hospitalization were collected. Cox regression was performed for mortality and recurrence, and multiple linear regression for duration of hospitalization.

Results

145 patients were included, with median age 60.0 years and 52.4% female. Psoas cross-sectional area was an independent risk factor for overall mortality (HR = 2.68, 95% CI 1.64–4.38, p < 0.001) and recurrence (HR = 2.31, 95% CI 1.14–4.65, p = 0.020), while post-operative CFS was an independent risk factor for overall mortality (HR = 1.88, 95% CI 1.14–3.09, p = 0.013). Post-operative CFS (β = 15.69, 95% CI 7.67–23.72, p < 0.001) and increase in CFS (β = 11.71, 95% CI 3.91–19.51, p = 0.004) were independently associated with increased duration of hospitalization.

Conclusion

In patients with surgically treated brain metastases, psoas cross-sectional area was an independent risk factor for mortality and recurrence, while post-operative CFS was an independent risk factor for mortality. Post-operative frailty and increase in CFS significantly increased duration of hospitalization. Measurement of psoas cross-sectional area and CFS may aid in risk stratification of surgical candidates for brain metastases.

Nur mit Berechtigung zugänglich

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31. https://doi.org/10.1093/ageing/afy169CrossRefPubMed

Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K (2013) Frailty in elderly people. Lancet 381:752–762. https://doi.org/10.1016/s0140-6736(12)62167-9CrossRefPubMed

Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarter RJ, Gutierrez Robledo LM, Rockwood K, von Haehling S, Vandewoude MF, Walston J (2013) Frailty consensus: a call to action. J Am Med Dir Assoc 14:392–397. https://doi.org/10.1016/j.jamda.2013.03.022CrossRefPubMedPubMedCentral

Rodríguez-Mañas L, Féart C, Mann G, Viña J, Chatterji S, Chodzko-Zajko W, Gonzalez-Colaço Harmand M, Bergman H, Carcaillon L, Nicholson C, Scuteri A, Sinclair A, Pelaez M, Van der Cammen T, Beland F, Bickenbach J, Delamarche P, Ferrucci L, Fried LP, Gutiérrez-Robledo LM, Rockwood K, Rodríguez Artalejo F, Serviddio G, Vega E (2013) Searching for an operational definition of frailty: a Delphi method based consensus statement: the frailty operative definition-consensus conference project. J Gerontol A Biol Sci Med Sci 68:62–67. https://doi.org/10.1093/gerona/gls119CrossRefPubMed

Au PC, Li HL, Lee GK, Li GH, Chan M, Cheung BM, Wong IC, Lee VH, Mok J, Yip BH, Cheng KK, Wu CH, Cheung CL (2021) Sarcopenia and mortality in cancer: a meta-analysis. Osteoporos Sarcopenia 7:S28-s33. https://doi.org/10.1016/j.afos.2021.03.002CrossRefPubMedPubMedCentral

Shachar SS, Williams GR, Muss HB, Nishijima TF (2016) Prognostic value of Sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58–67. https://doi.org/10.1016/j.ejca.2015.12.030CrossRefPubMed

Luo L, Shen X, Fang S, Wan T, Liu P, Li P, Tan H, Fu Y, Guo W, Tang X (2023) Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis. BMC Cancer 23:127. https://doi.org/10.1186/s12885-023-10582-2CrossRefPubMedPubMedCentral

Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, Young J (2015) The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 26:1091–1101. https://doi.org/10.1093/annonc/mdu540CrossRefPubMed

Mima K, Miyanari N, Morito A, Yumoto S, Matsumoto T, Kosumi K, Inoue M, Mizumoto T, Kubota T, Baba H (2020) Frailty is an independent risk factor for recurrence and mortality following curative resection of stage I–III colorectal cancer. Ann Gastroenterol Surg 4:405–412. https://doi.org/10.1002/ags3.12337CrossRefPubMedPubMedCentral

10.

Dai S, Yang M, Song J, Dai S, Wu J (2021) Impacts of frailty on prognosis in lung cancer patients: a systematic review and meta-analysis. Front Med (Lausanne) 8:715513. https://doi.org/10.3389/fmed.2021.715513CrossRefPubMed

11.

Komici K, Bencivenga L, Navani N, D’Agnano V, Guerra G, Bianco A, Rengo G, Perrotta F (2022) Frailty in patients with lung cancer: a systematic review and meta-analysis. Chest 162:485–497. https://doi.org/10.1016/j.chest.2022.02.027CrossRefPubMed

12.

Klingenschmid J, Krigers A, Pinggera D, Kerschbaumer J, Thomé C, Freyschlag CF (2022) The clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma. J Neurooncol 158:15–22. https://doi.org/10.1007/s11060-022-04001-yCrossRefPubMedPubMedCentral

13.

Ryan AM, Prado CM, Sullivan ES, Power DG, Daly LE (2019) Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition 67–68:110539. https://doi.org/10.1016/j.nut.2019.06.020CrossRefPubMed

14.

Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL, Han HQ (2010) Reversal of cancer Cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142:531–543. https://doi.org/10.1016/j.cell.2010.07.011CrossRefPubMed

15.

Williams GR, Dunne RF, Giri S, Shachar SS, Caan BJ (2021) Sarcopenia in the older adult with cancer. J Clin Oncol 39:2068–2078. https://doi.org/10.1200/jco.21.00102CrossRefPubMedPubMedCentral

16.

Chen JA, Splenser A, Guillory B, Luo J, Mendiratta M, Belinova B, Halder T, Zhang G, Li YP, Garcia JM (2015) Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle 6:132–143. https://doi.org/10.1002/jcsm.12023CrossRefPubMedPubMedCentral

17.

Barreto R, Mandili G, Witzmann FA, Novelli F, Zimmers TA, Bonetto A (2016) Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front Physiol 7:472. https://doi.org/10.3389/fphys.2016.00472CrossRefPubMedPubMedCentral

18.

Li H, Manwani B, Leng SX (2011) Frailty, inflammation, and immunity. Aging Dis 2:466–473PubMedPubMedCentral

19.

Furtner J, Berghoff AS, Albtoush OM, Woitek R, Asenbaum U, Prayer D, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Aretin B, Bartsch R, Zielinski CC, Schöpf V, Preusser M (2017) Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. Eur Radiol 27:3167–3173. https://doi.org/10.1007/s00330-016-4707-6CrossRefPubMedPubMedCentral

20.

Furtner J, Berghoff AS, Schöpf V, Reumann R, Pascher B, Woitek R, Asenbaum U, Pelster S, Leitner J, Widhalm G, Gatterbauer B, Dieckmann K, Höller C, Prayer D, Preusser M (2018) Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases. J Neurooncol 140:173–178. https://doi.org/10.1007/s11060-018-2948-8CrossRefPubMedPubMedCentral

21.

Ilic I, Faron A, Heimann M, Potthoff AL, Schäfer N, Bode C, Borger V, Eichhorn L, Giordano FA, Güresir E, Jacobs AH, Ko YD, Landsberg J, Lehmann F, Radbruch A, Herrlinger U, Vatter H, Schuss P, Schneider M (2021) Combined assessment of preoperative frailty and sarcopenia allows the prediction of overall survival in patients with lung cancer (NSCLC) and surgically treated brain metastasis. Cancers (Basel). https://doi.org/10.3390/cancers13133353CrossRefPubMed

22.

Cho A, Hennenberg J, Untersteiner H, Hirschmann D, Gatterbauer B, Zöchbauer-Müller S, Hochmair MJ, Preusser M, Rössler K, Dorfer C, Frischer JM, Furtner J (2022) Influence of temporal muscle thickness on the outcome of radiosurgically treated patients with brain metastases from non-small cell lung cancer. J Neurosurg. https://doi.org/10.3171/2021.12.Jns212193CrossRefPubMed

23.

Khalafallah AM, Jimenez AE, Patel P, Huq S, Azmeh O, Mukherjee D (2020) A novel online calculator predicting short-term postoperative outcomes in patients with metastatic brain tumors. J Neurooncol 149:429–436. https://doi.org/10.1007/s11060-020-03626-1CrossRefPubMedPubMedCentral

24.

Heimann M, Schäfer N, Bode C, Borger V, Eichhorn L, Giordano FA, Güresir E, Jacobs AH, Ko YD, Landsberg J, Lehmann F, Radbruch A, Schaub C, Schwab KS, Weller J, Herrlinger U, Vatter H, Schuss P, Schneider M (2021) Outcome of elderly patients with surgically treated brain metastases. Front Oncol 11:713965. https://doi.org/10.3389/fonc.2021.713965CrossRefPubMedPubMedCentral

25.

Kerschbaumer J, Krigers A, Demetz M, Pinggera D, Klingenschmid J, Pichler N, Thomé C, Freyschlag CF (2022) The clinical Frailty Scale as useful tool in patients with brain metastases. J Neurooncol 158:51–57. https://doi.org/10.1007/s11060-022-04008-5CrossRefPubMedPubMedCentral

26.

Landi F, Calvani R, Cesari M, Tosato M, Martone AM, Bernabei R, Onder G, Marzetti E (2015) Sarcopenia as the biological substrate of physical frailty. Clin Geriatr Med 31:367–374. https://doi.org/10.1016/j.cger.2015.04.005CrossRefPubMed

27.

Schaap LA, Pluijm SM, Deeg DJ, Harris TB, Kritchevsky SB, Newman AB, Colbert LH, Pahor M, Rubin SM, Tylavsky FA, Visser M (2009) Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci 64:1183–1189. https://doi.org/10.1093/gerona/glp097CrossRefPubMed

28.

Davies B, García F, Ara I, Artalejo FR, Rodriguez-Mañas L, Walter S (2018) Relationship between Sarcopenia and frailty in the toledo study of healthy aging: a population based cross-sectional study. J Am Med Dir Assoc 19:282–286. https://doi.org/10.1016/j.jamda.2017.09.014CrossRefPubMed

29.

Cuschieri S (2019) The STROBE guidelines. Saudi J Anaesth 13:31–34. https://doi.org/10.4103/sja.SJA_543_18CrossRef

30.

Zakaria HM, Wilkinson BM, Pennington Z, Saadeh YS, Lau D, Chandra A, Ahmed AK, Macki M, Anand SK, Abouelleil MA, Fateh JA, Rick JW, Morshed RA, Deng H, Chen K-Y, Robin A, Lee IY, Kalkanis S, Chou D, Park P, Sciubba DM, Chang V (2020) Sarcopenia as a prognostic factor for 90-day and overall mortality in patients undergoing spine surgery for metastatic tumors: a multicenter retrospective cohort study. Neurosurgery 87:1025–1036. https://doi.org/10.1093/neuros/nyaa245CrossRefPubMed

31.

Church S, Rogers E, Rockwood K, Theou O (2020) A scoping review of the clinical Frailty Scale. BMC Geriatr 20:393. https://doi.org/10.1186/s12877-020-01801-7CrossRefPubMedPubMedCentral

32.

Winther RR, Hjermstad MJ, Skovlund E, Aass N, Helseth E, Kaasa S, Yri OE, Vik-Mo EO (2022) Surgery for brain metastases-impact of the extent of resection. Acta Neurochir (Wien) 164:2773–2780. https://doi.org/10.1007/s00701-021-05104-7CrossRefPubMed

33.

Richards SJG, Senadeera SC, Frizelle FA (2020) Sarcopenia, as assessed by Psoas cross-sectional area, is predictive of adverse postoperative outcomes in patients undergoing colorectal cancer surgery. Dis Colon Rectum 63:807–815. https://doi.org/10.1097/dcr.0000000000001633CrossRefPubMed

34.

Leitner J, Pelster S, Schöpf V, Berghoff AS, Woitek R, Asenbaum U, Nenning KH, Widhalm G, Kiesel B, Gatterbauer B, Dieckmann K, Birner P, Prayer D, Preusser M, Furtner J (2018) High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases. PLoS ONE 13:e0207849. https://doi.org/10.1371/journal.pone.0207849CrossRefPubMedPubMedCentral

35.

Rinkinen J, Zhang P, Wang L, Enchakalody B, Terjimanian M, Holcomb S, Wang SC, Buchman SR, Levi B (2013) Novel temporalis muscle and fat pad morphomic analyses aids preoperative risk evaluation and outcome assessment in nonsyndromic craniosynostosis. J Craniofac Surg 24:250–255. https://doi.org/10.1097/SCS.0b013e31827006f5CrossRefPubMed

36.

Nozoe M, Kubo H, Kanai M, Yamamoto M, Okakita M, Suzuki H, Shimada S, Mase K (2021) Reliability and validity of measuring temporal muscle thickness as the evaluation of Sarcopenia risk and the relationship with functional outcome in older patients with acute Stroke. Clin Neurol Neurosurg 201:106444. https://doi.org/10.1016/j.clineuro.2020.106444CrossRefPubMed

37.

Muglia R, Simonelli M, Pessina F, Morenghi E, Navarria P, Persico P, Lorenzi E, Dipasquale A, Grimaldi M, Scorsetti M, Santoro A, Politi LS (2021) Prognostic relevance of temporal muscle thickness as a marker of Sarcopenia in patients with glioblastoma at diagnosis. Eur Radiol 31:4079–4086. https://doi.org/10.1007/s00330-020-07471-8CrossRefPubMed

38.

Kawaguchi Y, Hanaoka J, Ohshio Y, Okamoto K, Kaku R, Hayashi K, Shiratori T, Akazawa A (2021) Sarcopenia increases the risk of post-operative recurrence in patients with non-small cell lung cancer. PLoS ONE 16:e0257594. https://doi.org/10.1371/journal.pone.0257594CrossRefPubMedPubMedCentral

39.

Xiong J, Wu Y, Hu H, Kang W, Li Y, Jin P, Shao X, Li W, Tian Y (2022) Prognostic significance of preoperative Sarcopenia in patients with gastric cancer liver metastases receiving hepatectomy. Front Nutr 9:878791. https://doi.org/10.3389/fnut.2022.878791CrossRefPubMedPubMedCentral

40.

Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, Steiner MS (2011) Muscle wasting in cancer Cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 62:265–279. https://doi.org/10.1146/annurev-med-061509-131248CrossRefPubMed

41.

Tsukioka T, Nishiyama N, Izumi N, Mizuguchi S, Komatsu H, Okada S, Toda M, Hara K, Ito R, Shibata T (2017) Sarcopenia is a novel poor prognostic factor in male patients with pathological stage I non-small cell lung cancer. Jpn J Clin Oncol 47:363–368. https://doi.org/10.1093/jjco/hyx009CrossRefPubMed

42.

Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8:457–465. https://doi.org/10.1038/nrendo.2012.49CrossRefPubMed

43.

Stone K, Zwiggelaar R, Jones P, Mac Parthaláin N (2022) A systematic review of the prediction of hospital length of stay: towards a unified framework. PLOS Digit Health 1:e0000017. https://doi.org/10.1371/journal.pdig.0000017CrossRefPubMedPubMedCentral

44.

Baek H, Cho M, Kim S, Hwang H, Song M, Yoo S (2018) Analysis of length of hospital stay using electronic health records: a statistical and data mining approach. PLoS ONE 13:e0195901. https://doi.org/10.1371/journal.pone.0195901CrossRefPubMedPubMedCentral

45.

Chang KC, Tseng MC, Weng HH, Lin YH, Liou CW, Tan TY (2002) Prediction of length of stay of first-ever ischemic stroke. Stroke 33:2670–2674. https://doi.org/10.1161/01.str.0000034396.68980.39CrossRefPubMed

46.

Doctoroff L, Herzig SJ (2020) Predicting patients at risk for prolonged hospital stays. Med Care 58:778–784. https://doi.org/10.1097/mlr.0000000000001345CrossRefPubMedPubMedCentral

47.

Cesari M, Landi F, Vellas B, Bernabei R, Marzetti E (2014) Sarcopenia and physical frailty: two sides of the same coin. Front Aging Neurosci 6:192. https://doi.org/10.3389/fnagi.2014.00192CrossRefPubMedPubMedCentral

48.

Lin YH, Chung CT, Chen CH, Cheng CJ, Chu HJ, Chen KW, Yeh SJ, Tsai LK, Lee CW, Tang SC, Jeng JS (2023) Association of temporalis muscle thickness with functional outcomes in patients undergoing endovascular thrombectomy. Eur J Radiol 163:110808. https://doi.org/10.1016/j.ejrad.2023.110808CrossRefPubMed

49.

Jones KI, Doleman B, Scott S, Lund JN, Williams JP (2015) Simple psoas cross-sectional area measurement is a quick and easy method to assess Sarcopenia and predicts major surgical complications. Colorectal Dis 17:20–26. https://doi.org/10.1111/codi.12805CrossRef

Titel: Effect of sarcopenia and frailty on outcomes among patients with brain metastases
verfasst von: Mervyn Jun Rui Lim
Zheting Zhang
Yilong Zheng
Ivan Wei Loon Khoo
Rhianne Caitlin Vaz Xin Ying
Sophie Jia Qian Koh
Ethanyn Lim
Pei Ing Ngam
Betsy Soon
Ying Liang Low
Li Feng Tan
Kejia Teo
Vincent Diong Weng Nga
Tseng Tsai Yeo
Publikationsdatum: 02.03.2024
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2024
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-023-04542-w

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization

The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma

Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors

Stereotactic radiosurgery for intracranial adenoid cystic carcinoma

Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review